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Abstract
Introduction Bone morphogenetic proteins (BMPs) are critical
growth factors in the osteogenic differentiation of progenitor
cells during development in embryos and fracture repair in
adults. Although recombinant BMPs are in use clinically, their
clinical efficiency needs to be improved. The biological activities
of BMPs are naturally regulated by extracellular binding proteins.
The specific hypotheses tested in this study were as follows: the
BMP inhibitor chordin is produced endogenously during the
osteogenic differentiation of human mesenchymal stem cells
(MSCs); and blockade of the activity of the BMP inhibitor
increases the rate of osteogenic differentiation of human MSCs
in vitro.
Methods Human MSCs were derived from bone marrow from
an iliac crest aspirate and from patients undergoing hip
hemiarthroplasty. The MSCs were induced down the
osteogenic pathway using standard osteogenic differentiation
media, and expressions of BMP-2 and chordin were determined
by gene expression analysis. During osteogenic differentiation,
chordin knockdown was induced using RNA interference.
Osteogenic differentiation was assessed by measuring the
expression of alkaline phosphatase and calcium deposition. The
differences in expression of osteogenic makers between groups
were compared by analysis of variance, followed by Gabriel post
hoc test.
Results We demonstrate the expression of BMP-2 and chordin
in human MSCs during osteogenic differentiation. Knockdown
of chordin by RNA interference in vitro resulted in a significant
increase in the expression of the osteogenic marker alkaline
phosphatase and the deposition of extracellular mineral, in
response to osteogenic stimulation.
Conclusion We conclude that endogenously produced chordin
constrains the osteogenic differentiation of human MSCs. The
targeting of BMP inhibitors, such as chordin, may provide a
novel strategy for enhancing bone regeneration.
Introduction
Bone regeneration is regulated by a number of growth factors,
among which the bone morphogenetic proteins (BMPs) have
received considerable attention because of their clinical appli-
cations. BMPs exert a wide range of effects on cells and tis-
sues that are involved in the repair process, including
recruitment of mesenchymal stem cell (MSCs) from surround-
ing tissues to the fracture site, their proliferation and differen-
tiation into osteoblasts and chondrocytes, and invasion of
blood vessels.
Cellular responses to BMPs are initiated by their binding to
transmembrane receptors, whose cytoplasmic domains
become phosphorylated at specific serine and threonine resi-
dues, thereby triggering Smad intracellular signalling path-
ways [1]. The biological activities of BMPs can be modulated
extracellularly by several binding proteins, including noggin,
gremlin, follistatin and chordin. The latter is a BMP antagonist
that was initially characterised in the Spemann organizer. It is
a 120 kDa protein, containing four cysteine-rich domains of
about 79 amino acids each [2-4], which bind to BMP-2 and
BMP-4, thereby preventing their interaction with BMP recep-
tors [2].
Endogenous BMP production is an essential component of
normal membranous ossification [5] and the early stages of
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fracture healing [6]. Using a well characterized in vitro model,
it was shown that BMP-2 is expressed endogenously by bone
marrow cells, with a level of expression that is dependent on
the degree of cellular osteogenic differentiation [7-9]. Moreo-
ver, antagonism of endogenous BMP signalling reduces the
osteogenic differentiation of a murine preosteoblastic cell line
[10].
The exogenous addition of individual BMPs can stimulate
osteogenic differentiation of MSCs [8,11,12] and promote
fracture healing in animal models [13-15]. Recombinant
human BMP-2 and BMP-7 are used clinically in spinal fusion
and the healing of tibial fractures. To obtain a clinically accept-
able result, these proteins are used at wildly supraphysiologi-
cal, highly expensive concentrations, and there is a pressing
need to improve their efficiency. In this paper, we identify chor-
din as an important endogenous inhibitor of the osteogenic dif-
ferentiation of human MSCs that could be targeted to improve
fracture repair.
Materials and methods
All chemicals used were from Sigma-Aldrich (St. Louis, MO,
USA), unless stated otherwise.
Culture of human mesenchymal stem cells
Human MSCs were obtained from two sources, the first one
being a commercially available bone marrow aspirate from a
19-year-old male donor (Clonetics-Poietics, Walkersville, MD,
USA). This was plated at 10 μl aspirate/cm2 on a 150 cm2 tis-
sue culture plate (Costar, Cambridge, MA, USA) and culti-
vated until confluency in 25 ml of basal medium (BM),
Dulbecco's modified Eagle's medium (DMEM) containing
1,000 mg/l glucose (Invitrogen Life Technologies, Carlsbad,
CA, USA), supplemented with 10% foetal bovine serum (FBS;
Stem Cell Technologies, Vancouver, Canada), which had
been commercially screened from carefully selected lots, and
1% antibiotic-antimycotic (Invitrogen). MSCs were selected
from the marrow aspirate on the basis of their ability to adhere
to tissue culture plastic. Nonadherent, haematopoietic cells
were removed during the first medium replacement after 3
days in culture. Primary culture human MSCs were subse-
quently detached using 0.25% trypsin/1 mmol/l EDTA (Invitro-
gen), replated at 1,000 cells/cm2, and cultured until
confluency to generate first passage MSCs. These were fro-
zen in Recovery Cell Culture Freezing Medium (Invitrogen),
stored in liquid nitrogen, and further expanded for osteogenic
differentiation studies at the appropriate time.
The second source of human MSCs was an Institutional
Review Board approved aspiration of the medullary cavities of
femora of four patients undergoing hip hemiarthroplasty, as
described previously [16]. There were three female patients
aged 71, 76 and 78 years, and a male aged 77 years. Briefly,
the marrow cells were layered on Ficoll (Sigma-Aldrich) and
centrifuged for 30 minutes at 400 g. The mononuclear cells
collected from the Ficoll-supernatant interface were cultured
in BM at a density of 5 × 107 per 75 cm2 flasks (Becton Dick-
inson, Franklin Lakes, NJ, USA). After 2 weeks in primary cul-
ture, cells were passaged at seeding densities between 100
and 1,000 cells/cm2, trypsinised and stored in Recovery Cell
Culture Freezing Medium in liquid nitrogen.
Before osteogenic differentiation, 6,000 cells/cm2 of human
MSCs were seeded in BM in each well of 24-well plates (Bec-
ton Dickinson Labware, Franklin Lakes, NJ, USA). Each exper-
imental condition was repeated in quadruplicate. On day 1 of
culture, approximately 24 hours after cells were seeded, BM
was removed and immediately replaced with an appropriate
volume of osteogenic differentiation medium (OM) consisting
of DMEM with 4,500 mg/l glucose (Invitrogen) supplemented
with 10% FBS (Stem Cell Technologies), 1% antibiotics, and
the osteogenic stimulants 100 nmol/l dexamethasone, 50 μg/
ml ascorbate phosphate and 3 mmol/l β-glycerophosphate.
First to third passage cells were used for osteogenic differen-
tiation studies. Media of all cultures was changed every 3
days.
Measurement of alkaline phosphatase activity and in 
vitro mineralisation
Osteogenic differentiation of human MSCs was evaluated
after 10 and 21 days in BM or OM. Medium was aspirated
directly from the wells. Cultures were quantitatively compared
on the basis of the expression of alkaline phosphatase (ALP)
activity and incorporation of calcium in the extracellular matrix.
The deposition of a mineralized matrix was further examined by
staining with Alizarin Red.
Alkaline phosphatase assay
ALP activity was determined by measuring the conversion of
p-nitrophenyl phosphate to p-nitrophenol. The substrate solu-
tion was prepared by dissolving 4-nitrophenyl phosphate dis-
odium salt hexahydrate into a substrate buffer consisting of 50
mmol/l glycine and 1 mmol/l MgCl2 at a pH of 10.5. Cultures
were washed twice with phosphate-buffered saline (PBS) and
250 μl of the substrate solution was added to each well. Fol-
lowing a 15-minute incubation, the resulting solution was
transferred to tubes containing the same volume of 1 mol/l
NaOH. The cells were immediately washed with PBS twice
and solubilized with a cell lysis buffer for protein assay. The cell
lysis buffer consisted of 50 mmol/l Tris, 150 mmol/l NaCl and
0.2% Triton X-100 (Fisher Biotech, Fairland, NJ, USA; pH
7.2).
The quantity of p-nitrophenol liberated from the substrate was
determined by comparison to a standard curve. The absorb-
ance was read at 405 nm on a UVmax Kinetic Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA). Readings
were obtained within the linear range of the standard curve.
ALP activity was normalized to the number of cells (as deter-Available online http://arthritis-research.com/content/10/3/R65
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mined by the WST-1 assay described below) and expressed
as nitrophenol product/minute/absorbance.
Mineral formation
The calcium deposition assay was based on that of Hanada
and coworkers [17]. Briefly, cultures were washed twice with
PBS. Mineral was then collected after dissolution with 300 μl
of 0.6 mol/l hydrocholoric acid at room temperature overnight
and the samples assayed the following day. Incorporation of
calcium in the extracellular matrix was quantified using the
commercial diagnostic kit QuantiChrom Calcium Assay Kit
(DICA-500; Bio Assay Systems, Hayward, CA, USA), in
accordance with the manufacturer's instructions. Absorb-
ances were compared with curves prepared using standard
solutions of calcium. Calcium deposition was expressed as
μmoles per tissue culture well (μmol/well).
Cytochemical staining
Human MSCs were plated and cultured as described above.
After culturing for 10 days, the media were aspirated and the
cells washed twice in PBS. A commercially available kit
(Sigma-Aldrich) was used for the cytochemical demonstration
of ALP activity with Neutral Red Solution counterstian. Repre-
sentative pictures at 10× magnification were taken with a
Leica Microscope DM IL (Leica Microsystems, Bannockburn,
IL, USA) and a Kodak DC 290 200 M digital camera (Eastman
Kodak, Rochester, NY, USA).
Mineral deposition was also assessed by staining with Alizarin
Red, after 21 days exposure to test the media. Monolayers in
the 24-well plates were washed with PBS and fixed in 10%
(vol/vol) formaldehyde (Sigma-Aldrich) at room temperature
for 15 minutes. The monolayers were then washed twice with
excess distilled water before addition of 250 μl of 40 mmol/l
of Alizarin Red solution (pH 4.1) per well. The plates were
incubated at room temperature for 10 minutes with gentle
shaking. After aspiration of the unincorporated dye, the wells
were washed four times with 1 ml distilled water while shaking
for 5 minutes. The plates were then left at an angle for 2 min-
utes to facilitate removal of excess water and reaspirated.
Small interfering RNA knockdown of chordin expression
Chordin expression was knocked down with chordin small
interfering RNA (siRNA; Qiagen, Valencia, CA, USA), which
was designed and synthesized by Qiagen based on the
sequence of human chordin (Gene Accession Number:
NM_003741). A 20 μmol/l working solution was made using
the siRNA suspension buffer provided by the manufacturer.
Preliminary experiments were conducted first to determine the
optimal concentration of siRNA to use in this in vitro system,
and secondly to select the siRNA candidate with the highest
efficiency in knocking down the target mRNA.
BLOCK-iT Fluorescent Oligo (Invitrogen) was used to assess
the transfection efficiency of siRNA. It is a fluorescein-labelled,
double-stranded RNA duplex with the same length, charge
and configuration as standard siRNA. The sequence of the
BLOCK-iT Fluorescent Oligo is not homologous to any known
gene, ensuring against nonspecific cellular events caused by
the introduction of the oligonucleotide into the cells. Human
MSCs were seeded under the same experimental conditions
and transfected with BLOCK-iT Oligo at varying concentra-
tions. After 24 hours, the proportion of cells transfected was
determined using a Cytomics FC500 MPL flow cytometer
(Beckman Coulter, Fullerton, CA, USA) and Flow Jo flow
cytometry analysis software (Tree Star, Ashland, OR, USA).
The most effective chordin siRNA used was targeted to the
sequence 5'-CAG GTG CAC ATA GCC AAC CAA-3'. The
sense sequence of the siRNA used was r(GGU GCA CAU
AGC CAA CCA A)dTdT and the antisense sequence was
r(UUG GUU GGC UAU GUG CAC C)dTdG. This was gener-
ated by the Qiagen HiPerformance siRNA Design Algorithm.
A scrambled siRNA nucleotide sequence (catalog number
1022076; Qiagen) with no significant homology to any mam-
malian gene (sense: UUC UCC GAA GUC ACG UdTdT; and
antisense: ACG UGA CAC GUU CGG AGA AdTdT) was
used as a negative control.
Human MSCs were transfected with siRNA 24 hours after
plating onto 24-well plates. On the day of the transfection, the
culture medium in each well was replaced with 400 μl of Opti-
MEM I Reduced Serum Medium (Invitrogen) without FBS or
antibiotics. The siRNA was prepared according to the manu-
facturer's instructions and it was added to each well at a final
concentration of 300 nmol/l. Lipofectamine 2000 at 2% (vol/
vol) and chordin-siRNA were used in a total transfection vol-
ume of 511 μl/well. Appropriate cell, Lipofectamine 2000 and
negative siRNA controls were established in parallel. The cells
were incubated at 37°C in a humidified carbon dioxide incuba-
tor for 16 to 24 hours and replaced with either BM or OM. The
cells transfected with siRNA were examined 3 and 10 days
after transfection and used for RNA expression assays.
Cell proliferation assay
Human MSC proliferation was assessed as a function of met-
abolic activity using the WST-1 assay (Roche Applied Sci-
ence, Indianapolis, IA, USA) [18]. Briefly, 1,000 cells were
plated in each well of a 96-well plate. After an overnight incu-
bation, the cells were exposed to the relevant test media, as
described above. Following treatment, media were removed
from each well and replaced with 100 μl fresh DMEM with
4,500 mg/l glucose, to which 10 μl WST-1 test solution was
then added. After 4 hours of incubation, absorbance was
measured using a UVmax Kinetic Microplate Reader (Molecu-
lar Devices, Sunnyvale, CA, USA) at a test wavelength of 450
nm and reference wavelength of 610 nm. The cell-free blank
value was then subtracted from each value. Results are
reported as the average of OD from the four wells point ±
standard deviation.Arthritis Research & Therapy    Vol 10 No 3    Kwong et al.
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Gene expression analysis
To analyze gene expression under a given experimental condi-
tion, human MSCs were seeded at the same density as above
in BM in three wells of a 12-well plate. After an overnight incu-
bation, the cells were exposed to the relevant media and
appropriate conditions. To test the efficacy of chordin siRNA
in ablating the expression of chordin transcripts, human MSCs
were transfected with scrambled (control siRNA) or chordin
siRNA for 24 hours and then exposed to the relevant media. At
the appropriate time, total RNA was collected by scraping
each well with a Fisherbrand cell scraper (Fisher Scientific,
Pittsburgh, PA, USA) in PBS, pelleting the cells and collecting
the RNA in RNA Later solution (Ambion, Austin, TX, USA) at -
80°C.
To extract RNA, samples were first suspended in 1 ml cold Tri-
zol (Invitrogen) and choloroform added before centrifugation
to enable phase separation. RNA was precipitated by addition
of isopropanol to the aqueous phase, followed by further cen-
trifugation. Precipitated RNA pellets were washed in 75% eth-
anol and re-suspended in distilled RNAse-free water before
being quantified using a NanoDrop ND-1000 spectrophotom-
eter (Labtech International, East Sussex, UK). All samples
were treated with DNAse I (Invitrogen) to remove any potential
contaminating DNA in the specimen. The DNAse was subse-
quently inactivated by the addition of EDTA, before reverse
transcription.
RT-PCR was performed to evaluate the expression of BMP-2
and chordin, using the housekeeping gene GAPDH (glyceral-
dehyde 3-phosphate dehydrogenase) as an internal control.
cDNA was generated using the High Capacity cDNA reverse
transcription Kit (Applied Biosystems, Warrington, UK). PCR
was performed using the Invitrogen Platinum Taq (Invitrogen)
method, in accordance with the manufacturer's instructions.
The PCR primers were designed on the basis of the published
human gene sequences (Table 1; Invitrogen). PCR amplica-
tion was performed using an MJ Research PTC-2000 Peltier
thermal cycler (GMI, Ramsey, MN, USA) in the following
sequence: denaturation at 94°C for 90 seconds followed by a
specific number cycles of denaturation (Table 1) at 94°C for
30 seconds, annealing at the temperature shown below for
each specific primer for 30 seconds, and extension at 72°C for
6 seconds followed by a last extension at 72°C for 10 minutes
(Table 1). A 20 μl aliquot of the PCR product was added to 10
μl loading buffer (consisting of 50% glycerol, 0.2 mol/l EDTA
[pH 8.0] and 0.05% bromophenol blue), and the resulting
solution electrophoresed on 2% agarose gel stained with
GelRed nucleic acid stain (Cambridge Biosciences, Cam-
bridge, UK). As well as the tested samples, a 100 base pair
DNA ladder (Hyperladder IV; Bioline, London, UK), a positive
control prepared from the reverse transcription of human total
RNA (Promega UK, Southampton, UK) and a negative control
of molecular biology grade water were also included on each
gel. Photographs of the gel were taken under ultraviolet light
with a Syngene high-resolution camera (Synoptics, Cam-
bridge, UK) and images acquired and stored with a Genesnap
software (Syngene, Cambridge, UK).
Statistical analysis
The data are expressed as mean ± standard deviation and
were analyzed using the statistical package SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL, USA). Statistical analyses
were performed using analysis of variance, followed by the
Gabriel post hoc test, with P < 0.05 considered to be statisti-
cally significant.
Results
Expression of chordin and BMP-2 during osteogenic 
differentiation of MSCs
MSCs were cultured in BM or OM for 20 days. The usual
change in phenotype of MSCs from spindle-shaped cells
(when cultured in BM) to more cuboidal-shaped cells (when
cultured in OM) was noted. The osteogenic phenotype of
MSCs was confirmed by the increase in ALP activity at day 10
(Figure 1) and positive Alizarin Red staining at day 21 for cells
cultured in OM, but not BM (Figure 1). These data confirm the
ability of human MSCs to undergo osteogenesis in response
to OM.
BMP-2 expression was weakly detectable in MSCs exposed
to 5 and 10 days of BM (Figure 2a). Osteogenic differentiation
induced an increase in the expression of BMP-2 (Figure 2a).
Table 1
Primers used for RT-PCR
Gene name Primer sequence Product length Annealing temperature Number of cycles
BMP-2 Forward: GCT CTT TCA ATG GAC GTG TC
Reverse: GCT CTG CTG AGG TGA TAA AC
514 bp 59°C 38
Chordin Forward: GAG AAC TTC AGG CCA ATG TC
Reverse: CAG TGG GTA TCC AAG GAA AG
654 bp 58°C 40
GAPDH Forward: CCA TCA CCA TCT TCC AGG AG
Reverse: CAT CCA CAG TCT TCT GGG TG
353 bp 60°C 32
bp, base pairs; BMP, bone morphogenetic protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.Available online http://arthritis-research.com/content/10/3/R65
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Chordin mRNA expression was not detectable by RT-PCR
when the MSCs were cultured in BM. However, there was
detectable expression of chordin transcripts in MSCs cultured
in OM, with an apparent increased expression at day 10 com-
pared with day 5 (Figure 2a).
Transfection and chordin knockdown by siRNA
To assess the effect of chordin knockdown on osteogenic dif-
ferentiation, we first determined whether we could transfect
siRNA into human MSCs, by using BLOCK-iT Oligo fluores-
cent siRNA and detecting its presence using a Cytomics
FC500 MPL flow cytometer. As measured by fluorescence-
labelled siRNA using a flow cytometer, transfection with 100,
200 and 300 nmol/l oligomucleotides respectively resulted in
51%, 91% and 99% efficiencies of transfection (Figure 3).
Based on these data, the dose of 300 nmol/l siRNA was used
in further experiments to screen the designed candidate
siRNAs.
Subsequently, the cells were transfected with chordin-specific
siRNA and were cultured for 3 days (for mRNA analysis), 10
days (for mRNA analysis and ALP assay), and 21 days (for cal-
cium deposition assay). After 3 and 10 days of culture, total
RNAs were extracted from the human MSCs. RT-PCR analy-
sis showed that the human MSCs transfected with chordin
siRNA had undetectable chordin gene expression, whereas
the control siRNA cells exhibited detectable chordin mRNA
expression (Figure 2b).
Knockdown of chordin expression in human MSCs
Effects on morphology and proliferation
There were no significant calcium deposits in cells cultured
with BM (Figure 1). There was no difference in morphology
between the control siRNA and chordin siRNA treated cells.
Human MSC proliferation in the presence of Lipofectamine
control, control siRNA and chordin siRNA was monitored for 7
days (as described in Materials and methods [above]). The rel-
ative number of cells was determined spectrophotometrically
using WST-1 assay at 3, 5 and 7 days of culture. After 5 and
7 days, cells treated with chordin siRNA had decreased prolif-
eration, as compared with untreated cells, and cells treated
with transfection reagent only or control siRNA (P < 0.005;
Figure 4).
Effects on osteogenic differentiation
We next examined the functional consequences of chordin
knockdown on the osteogenic differentiation of human MSCs
cultured in OM. MSCs were cultured for 10 or 21 days in OM
following transfection of chordin-specific siRNA. Treatment
with chordin siRNA, but not the control siRNA, resulted in an
approximately threefold increase of ALP expression relative to
untreated controls (Figure 5a). We also found that chordin
siRNA (but not control siRNA) treatment of human MSCs cul-
tured for 21 days in OM increased calcium mineral deposition
by approximately twofold, relative to untreated controls (Figure
5b). Consistent with this result, chordin siRNA treated cells
Figure 1
Response of human MSCs to osteogenic medium Response of human MSCs to osteogenic medium. Induction of an 
osteogenic phenotype of mesenchymal stem cells (MSCs) cultured in 
osteogenic media versus basal media, as demonstrated by alkaline 
phosphatase staining (Neutral Red counterstain) at day 10 and by Ali-
zarin Red stain at day 21.
Figure 2
Expression of BMP-2 and chordin transcripts during osteogenic differ- entiation of human mesenchymal stem cells Expression of BMP-2 and chordin transcripts during osteogenic differ-
entiation of human mesenchymal stem cells. (a) Temporal progression 
of bone morphogenetic protein (BMP)-2 and chordin expression during 
osteogenic differentiation of human MSCs over a 10-day period. 
Human MSCs were cultured in basal media (BM) or osteogenic media 
(OM) for 5 or 10 days. (b) Effect of small interfering RNA (siRNA) on 
chordin expression. Mesenchymal stem cells (MSCs) were transfected 
with either control or chordin siRNA and then grown in OM for the 3 or 
10 days. RNA was extracted and reverse transcribed, and PCR amplifi-
cation of chordin, BMP-2 and GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) sequences was performed.Arthritis Research & Therapy    Vol 10 No 3    Kwong et al.
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stained more intensely with Alizarin Red than those treated
with control siRNA (Figure 5c).
Discussion
In this study, expression of BMP-2 and chordin during the in
vitro  osteogenic differentiation of human MSCs was con-
firmed. BMP-2 transcripts were expressed constitutively by
MSCs cultured in BM. Induction of osteogenic differentiation
was associated with an increase in the expression of BMP-2.
Chordin mRNA expression was not detectable by conven-
tional PCR, when the MSCs were exposed to BM. However,
chordin expression was detectable when the cells were
induced down the osteogenic pathway, with apparently
increased expression at day 10 compared with day 5. These
findings confirm data from previous studies, in which the
expression of BMP-2 and chordin increased with the osteo-
genic differentiation of MSCs in this culture model system
[8,19]. Einhorn and colleagues [8] also demonstrated that the
blockade of endogenously produced BMP-2 activity with a
specific antibody reduced the osteogenic differentiation of
murine MSCs by 80%.
In the present study, it was further demonstrated that chordin
knockdown accelerates early osteogenesis and leads to
increased deposition of mineral at late time points. The sup-
pression of chordin led to an increase in the bioavailability of
endogenously produced BMP-2 to drive the differentiation of
Figure 3
Transfection efficiency of siRNA in relation to concentration Transfection efficiency of siRNA in relation to concentration. Final concentration of small interfering RNA (siRNA) in culture media in nanomoles/litre 
(nM). Histograph analysis of flow cytometry data shows the transfection efficiency of siRNA. The darker peak represents the fluorescence-positive 
cell population, which is clearly shifted from the position of the gated untransfected cells (lighter peaks). Upper univariate range indicates proportion 
of fluorescent cells. These data are representative of two independent experiments.
Figure 4
Effect of chordin siRNA on cellular proliferation Effect of chordin siRNA on cellular proliferation. Cellular proliferation 
was measured with the metabolic indicator WST-1 at the indicated 
periods after the start of culture. The cells were either not exposed to 
anything (Blank), to the transfection reagent Lipofectamine only (Lipo), 
or to the transfection reagent and a control siRNA (small interfering 
RNA) or chordin siRNA. The cells were then grown in osteogenic 
media for different periods. Each value is the mean ± standard devia-
tion of three independent experiments. *P < 0.005 versus control 
siRNA.Available online http://arthritis-research.com/content/10/3/R65
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erature suggesting that BMP antagonists of this type regulate
osteoblast differentiation and adult bone formation 5,20,21].
The exogenous application of chordin also limits in vitro oste-
ogenesis [19]. Overall, these findings confirm that BMP-2 is
important in driving and sustaining osteogenic differentiation
in this in vitro model. This effect of BMP-2 is blunted by the
known BMP inhibitor, chordin, which is concurrently
expressed during the osteogenic differentiation of the progen-
itor cells.
To date, biological methods of enhancing bone regeneration in
clinical use have centred around the promotion of
osteoinduction via the delivery of BMPs. However, targeting
BMP inhibitors, such as chordin, may provide a novel means of
improving fracture repair and fulfilling other relevant osteo-
genic needs.
Noggin is another extracellular BMP inhibitor, and has a mode
of action similar to that of chordin. The expression of the nog-
gin gene is essential for proper skeletal development [22].
Figure 5
Effect of chordin knockdown on the expression of markers of osteogenic differentiation in human MSCs Effect of chordin knockdown on the expression of markers of osteogenic differentiation in human MSCs. (a) Alkaline phosphatase (ALP) activity at 
day 10. (b) Calcium deposit at day 21. (c) Alizarin Red staining after 21 days in culture. Human mesenchymal stem cells (MSCs) were exposed to 
basal media, osteogenic media only (Blank), transfection reagent only in osteogenic media (Lipo), control small interfering RNA (siRNA) in osteo-
genic media, or chordin siRNA in osteogenic media. ALP activity is expressed as the mean ± standard deviation (nmol nitrophenol/minute/absorb-
ance) of independent experiments of cells from five donors. Calcium deposit is expressed as micromoles/well. *P < 0.005 versus the other groups.Arthritis Research & Therapy    Vol 10 No 3    Kwong et al.
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Transgenic mice over-expressing noggin in the bone microen-
vironment have decreased trabecular bone volume and
impaired osteoblastic function, leading to osteopenia and frac-
tures [20]. Noggin endogenous expression has been demon-
strated in animal models of fracture repair [23,24]. It was
recently reported that the suppression of noggin enhances
osteogenesis in murine cell lines and accelerates in vivo bone
formation in an intra-membranous animal model [25]. Whether
noggin is effective in human cells undergoing osteogenic dif-
ferentiation remains to be determined.
In addition to noggin and chordin, it is possible that a similar
enhancement of osteogenesis could be achieved through
reduced expression of other BMP antagonists. Our preliminary
results (data not shown) suggest that follistatin and gremlin
are also expressed during the osteogenic differentiation of
human MSCs. It remains uncertain which BMP inhibitor or
combination of inhibitors would produce the greatest effect.
As well as promoting osteogenesis, suppression of chordin
decreased cellular proliferation by 35%. This decrease in cel-
lular proliferation may be a result of an increase in the differen-
tiation of the MSCs, because there exists an inverse
relationship between proliferation and differentiation of osteo-
progenitor cells during bone formation [26]. Chordin suppres-
sion also leads to an increase in the bioavailability of BMP-2
and it was previously reported that BMP-2 decreases the pro-
liferation of human MSCs in osteogenic medium [11,27,28].
BMP-2 also induces an increase in the extracellular matrix of
osteoblastic cells in vitro and thereby contributes to a
decrease in their proliferation [27].
This study is limited by the relatively small number (five) of cell
donors on which the hypothesis was tested. However, we
believe that the findings in the study can be extrapolated to
cells from a large population of donors because there is con-
sistently a significant and large increase in expression of oste-
ogenic markers, as a result of chordin knockdown in cells from
all donors tested. Another factor to consider is whether the
age of the donors had an influence on the results of this study.
Four donors were over 70 years old and one donor was aged
19. The relative increase in expression of the osteogenic mark-
ers in the young donor, as a result of chordin knockdown, was
within the range of that of the donors over 70 years old. MSCs
from young donors are commercially available, but they are
expensive. On the other hand, cells derived from older donors
were obtained by collecting bone marrow, which would have
been discarded, at hip surgery. It is unlikely that there would
be any difference in the response of MSCs from donors of dif-
ferent age groups. The capacity of human MSCs to differenti-
ate into osteoblasts and adipocytes is maintained irrespective
of donor age [29]. Prior studies suggest that there are no
intrinsic defects in human MSCs with ageing and that extrinsic
factors present in the ageing environment of MSC may be
responsible for the impaired osteoblast functions observed
with ageing. Hormonal differences with ageing may be a factor
as sera obtained from aged donors are less potent inducers of
osteoblast differentiation of human MSC, as compared with
sera obtained from young donors [30].
Clinical application of these findings will require targeting
chordin or other such BMP antagonists in vivo. This may be
achieved with local injection of siRNA at the site of skeletal
injury, an approach that is yet to be validated in animal models.
Alternative approaches include the use of neutralizing antibod-
ies, gene transfer and the design of small molecule
antagonists.
Conclusion
We conclude that endogenously produced chordin constrains
the osteogenic differentiation of human MSCs. The targeting
of BMP inhibitors, such as chordin, provides a novel strategy
for enhancing bone regeneration.
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